Clinical Trial: Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)

U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07850739) titled 'Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)' on Sept. 23.

Brief Summary: The main objective of this study is to evaluate the efficacy of different dose levels of NBIP-01435 on reducing elevated androstenedione (A4) levels in adults with classic CAH.

Study Start Date: Dec. 01

Study Type: INTERVENTIONAL

Condition: Congenital Adrenal Hyperplasia

Intervention: DRUG: NBIP-01435

NBIP-01435 will be administered per schedule specified in the arm description.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Neurocrine Biosciences

Published ...